The Code Breaker Biography by Walter Isaacson — page 1

E C

E B

A K

1 / 24

The Code

Breaker

J E N N I F E R

D O U D N A

A N D

T H E

C R I S P R

R E V O L U T I O N

◆

Walter Isaacson

F I R S

E D I T I O N

2 / 24

The Code Breaker Biography by Walter Isaacson — page 3

P U B L I C

I O N

D AT A

THE CODE BREAKER: A BIOGRAPHY OF JENNIFER DOUDNA AND THE

CRISPR REVOLUTION.

First Edition, 2026.

This volume is an original biographical reference work, prepared

independently for print and digital distribution. It is not affiliated with, nor

authorized or endorsed by, Walter Isaacson, Jennifer Doudna, or any

publisher of previously published works bearing similar titles.

reserved. No part of this publication may be reproduced, stored in a

retrieval system, or transmitted in any form or by any means, electronic,

mechanical, photocopying, recording, or otherwise, without the prior written

permission of the publisher, except for brief quotations embodied in critical

articles and reviews.

Set in Source Serif 4, with Playfair Display and Inter display accents.

Composed as a digital document designed for A4 print production.

3 / 24

The Code Breaker Biography by Walter Isaacson — page 4

The genome is the longest sentence we know. For

most of human history we could only read it. Now

we can edit it—which means the question is no

longer what it says, but what we mean.

—

T H E

A U T H O

4 / 24

The Code Breaker Biography by Walter Isaacson — page 5

Contents

F R O N T

M AT T E R

Prologue—The Quiet Code

T H E

L I F E

A N D

S C I E N C E

Chapter One—Islands of Curiosity, 1964–1985

Chapter Two—The Shape of RNA, 1985–1994

Chapter Three—The Craft of Structure, 1994–2002

Chapter Four—The Repeats in the River, 2002–2011

Chapter Five—Collaboration in San Juan, 2011–2012

Chapter Six—The Gold Rush, 2012–2016

Chapter Seven—Editing the Human Story, 2016–2020

Chapter Eight—The Code Against the Virus, 2020

Chapter Nine—Stockholm in a Sickroom World, 2020

Chapter Ten—The Open Book, 2021–2026

Epilogue—The Responsibility of Knowing

B A C K

M AT T E R

Appendix A—Chronology

Appendix B—Principal Achievements

Appendix C—Honors and Awards

Appendix D—Legacy

Appendix E—A Note on Sources

5 / 24

The Code Breaker Biography by Walter Isaacson — page 6

L O

U E

The Quiet Code

n a June morning in 2012, a small group of scientists in Berkeley and Umeå sent a

manuscript into the world that most biologists were not yet ready to expect. It

appeared in

Science

on the twenty-eighth of that month, and it described a bacterial defense

system that could be programmed like a search engine. Tell the system a sequence, and it

would find that exact sequence among the three billion letters of a genome and cut it cleanly

in two. The authors called the machine CRISPR-Cas9. They knew, even then, that they had

opened a door.

Eight years later, on an October morning darkened by a global pandemic, Jennifer

Doudna and Emmanuelle Charpentier stood before video cameras in two countries to

receive the Nobel Prize in Chemistry. Between those two Junes lies one of the great scientific

adventures of the twenty-first century: a story of curiosity, rivalry, patents, scandal, and the

slow, patient work of understanding how a microbe remembers its enemies.

But the story begins much earlier, and much farther from any laboratory, on the

windward coast of an island in the Pacific, where a girl who loved the ocean and knew

nothing of Nobel prizes first learned that molecules could be read like sentences. This book

follows that girl from the volcanic soil of Hilo to the laboratories of the American mainland,

through a revolution in the understanding of RNA, and into the largest question a species

can ask of itself: now that the code of life can be rewritten, what shall we write?

6 / 24

The Code Breaker Biography by Walter Isaacson — page 7

H A P

Islands of Curiosity

1 9 6 4 – 1 9 8 5

ennifer Anne Doudna was born in Washington, D.C., on February 19, 1964, the daughter of

Martin Doudna, a historian who had earned his doctorate at the University of Michigan,

and Dorothy Doudna, who taught English. When Jennifer was seven, the family moved to

Hilo, on the Big Island of Hawaii, where her father had accepted a position teaching

American history at the University of Hawaii at Hilo. The campus was small, the island

smaller, and the Pacific was everywhere at once.

A single interlude in Havre, Montana, during her seventh-grade year taught her what

cold and flatness felt like; the family returned to Hawaii at the earliest opportunity, and she

never forgot the relief of coming home to trade winds and rain forests. On the island she

devoured books of popular science on the porch, ocean air curling the pages. James Watson’s

The Double Helix

arrived at exactly the right moment: here was science not as a list of facts

but as a chase, complete with personalities, mistakes, and late-night triumphs.

A demanding high school chemistry course gave the abstraction a shape. Molecules were

not pictures in a textbook; they were physical things that moved, collided, and sometimes

assembled themselves into the machinery of life. She wanted to understand that machinery

from the inside out.

She carried the ambition to Pomona College in California, where she majored in

chemistry, spending long afternoons in undergraduate laboratories and wondering whether

the chemistry of living systems could be studied with the precision of a crystallographer.

She graduated in 1985. Her professors encouraged her toward Harvard, where a young

biochemist named Jack Szostak was building one of the most adventurous laboratories in

the country. Hawaii had taught her patience and observation; the mainland would teach her

speed.

7 / 24

The Code Breaker Biography by Walter Isaacson — page 8

H A P

The Shape of RNA

1 9 8 5 – 1 9 9 4

t Harvard, Doudna joined the laboratory of Jack Szostak, a biochemist who liked to ask

questions so large that most of his peers considered them premature. Life, Szostak

reasoned, had almost certainly begun with RNA—a molecule that could store information

like DNA and catalyze chemistry like a protein. If that were true, an RNA molecule ought to

be able to copy itself. Doudna’s task was to find out how close RNA could come.

She spent four years building and dissecting self-splicing introns and other catalytic

RNAs, learning to treat a molecule as a mechanism: every atom had a job, every functional

group a reason. The training formed her permanently. Years later, colleagues would

describe her signature gift as the ability to look at a complex biological machine and see,

almost immediately, the thirty percent of it that mattered. She completed her doctorate in

1989, in RNA catalysis.

For postdoctoral work she chose Thomas Cech’s laboratory at the University of Colorado,

Boulder. Cech had shared the Nobel Prize in Chemistry in 1989 for discovering that RNA

could carry out catalysis. Her project was among the hardest in the lab: growing crystals of a

catalytic RNA so that its three-dimensional structure could be solved by X-ray

crystallography. For years the crystals refused to diffract, then refused to repeat themselves,

then refused to be interpreted. Doudna learned to treat failure as data. In 1996, with

collaborators at Yale, where she had by then moved, the structure of the P4–P6 domain of

the

Tetrahymena

group I intron finally came into focus—the first high-resolution look at the

folded architecture of a catalytic RNA.

More important than the structure was the stance she carried out of the experience: RNA

was not a mere messenger in the cell’s scheme; it was an ancient machine, capable of

folding into precise and functional shapes. If a molecule could be that sophisticated, RNA

biology would reward a lifetime of close attention. In 1994 Yale offered her a faculty position,

and she accepted.

8 / 24

The Code Breaker Biography by Walter Isaacson — page 9

H A P

H R

The Craft of Structure

1 9 9 4 – 2 0 0 2

t Yale, Doudna built a laboratory devoted to the architecture of RNA and of the

protein-RNA machines that use it. Her groups solved structures of molecules involved

in reading and translating genetic information—work that required patience, an eye for

disorder, and the willingness to try a hundred purification strategies for the sake of one

useful crystal. In 1997 she was named an investigator of the Howard Hughes Medical

Institute, a distinction that carried with it the freedom to work on what she believed

mattered most.

She also discovered, in those years, the two attachments that would anchor her life.

Teaching, she found, was a kind of crystallography: the teacher’s job was to remove the

noise until the signal stood clear. And in Jamie Cate, a fellow scientist she had met at

Harvard who later joined the faculty at Berkeley, she found a partner who shared her

appetite for molecular puzzles.

By the early 2000s, Doudna’s reputation as a structural biologist was secure. But a

restlessness had settled in. Structures, however beautiful, were photographs; she wanted

motion pictures. She wanted to understand not only what molecular machines looked like,

but how they decided what to do.

In 2002, the University of California, Berkeley, recruited her with a promise that suited

that ambition: a new building, a brilliant department, and the freedom to choose questions

at the boundary of chemistry, biochemistry, and biology. She moved her laboratory—and her

young family, including a son, Andrew, born that year—back to the Pacific coast, where the

university’s hillside laboratories looked out over the Golden Gate. It felt, after a decade of

New England winters, like coming home.

9 / 24

The Code Breaker Biography by Walter Isaacson — page 10

H A P

U R

The Repeats in the River

2 0 0 2 – 2 0 1 1

mong Doudna’s new colleagues was Jill Banfield, an environmental microbiologist who

sequenced DNA taken directly from the wild. Banfield’s most dramatic source was the

runoff of Iron Mountain, California, an abandoned mine so acidic that its waters could

dissolve metal. The microbial communities that lived there were unlike anything in a

culture flask, and their genomes—assembled piecemeal from environmental samples—

contained a recurring puzzle: stretches of short repeated sequences, interrupted by unusual

spacer DNA of unknown origin. The repeats already had a name, CRISPR, and a mystery.

Other laboratories supplied the first answers. In 2007, researchers at Danisco showed

that bacteria carrying the repeats acquired resistance to the viruses that matched their

spacers: CRISPR was an adaptive immune system. In 2008, John van der Oost’s group in the

Netherlands demonstrated that the system worked by copying fragments of the invaders’

DNA into RNA guides, which then directed CRISPR-associated proteins to slice matching

DNA. Bacteria, it turned out, kept a genetic wanted-poster of every enemy they had ever

survived.

Doudna found the mechanism irresistible. With her postdoctoral researcher Martin Jinek

and a growing team, she began to pull the machinery apart. One enzyme stood out: Cas9, a

single large protein carrying two nuclease blades, which could be steered by two short RNAs

to a specific site in a DNA molecule and cut it. It was as if a pair of scissors had been given a

postal address.

Her laboratory worked out how the guide RNAs loaded into the protein and how

recognition unfolded, base by base. What they could not yet say was whether the system

could be repurposed—whether the address could be chosen by a scientist rather than by

evolution. That question would be answered faster than anyone expected, because on the

other side of the Atlantic, a French microbiologist was asking the same thing.

10 / 24

The Code Breaker Biography by Walter Isaacson — page 11

H A P

I V E

Collaboration in San Juan

2 0 1 1 – 2 0 1 2

mmanuelle Charpentier had trained as a microbiologist in France before establishing

her own laboratory at Umeå University in Sweden. She was studying

Streptococcus

pyogenes

, the bacterium that causes strep throat, and she had noticed a strange feature: in

addition to the repeated sequences and the Cas proteins, the bacterium produced a second,

unassuming RNA that seemed essential to the system. In 2011, with Jörg Vogel’s group, she

demonstrated that this trans-activating RNA—tracrRNA—was the key that allowed the

system’s guide RNA to mature.

Doudna and Charpentier met in the spring of 2011 at a conference in San Juan, Puerto

Rico. The conversation, by all accounts, was electric: Charpentier needed biochemistry to

understand her tracrRNA and Cas9; Doudna needed biology to understand what her

structures were for. Over the following months, scientists in both laboratories—above all

Martin Jinek in Berkeley and Krzysztof Chylinski in Umeå, with Ines Fonfara joining at

critical moments—worked at a pace that neither group had known before. The result,

published in

Science

on June 28, 2012, was a reprogrammable, RNA-guided DNA

endonuclease: with a single engineered guide RNA, scientists could direct Cas9 to cut

essentially any site in any DNA molecule.

The paper’s title described the work as an advance in understanding bacterial adaptive

immunity, which it was. But every laboratory that read it understood the sentence that was

not written: if this machine works in a test tube, it will work in a cell; and if it works in a cell,

the genome of every organism on Earth becomes editable.

Patents were filed within weeks. Neither Doudna nor Charpentier imagined, at the time,

that the filings would ignite a decade of litigation—or that they were founding, however

unwittingly, an industry.

11 / 24

The Code Breaker Biography by Walter Isaacson — page 12

H A P

I X

The Gold Rush

2 0 1 2 – 2 0 1 6

he gold rush began in January 2013, when two papers appeared within days of each

other in

Science

—one from Feng Zhang’s laboratory at the Broad Institute and one from

George Church’s group at Harvard—showing that CRISPR-Cas9 could edit the genomes of

human and mouse cells. Doudna’s own laboratory, working with Charpentier’s, published

human-cell results in

eLife

within the same month. The era of genome editing had begun.

Then came the patent war. Doudna’s university and the Broad Institute both claimed the

intellectual territory, and in February 2017 the United States Patent and Trademark Office’s

Patent Trial and Appeal Board decided that the Broad Institute’s patents covering use of the

system in eukaryotic cells could stand, while leaving the university’s broader claims

unresolved; proceedings in Europe went the other way. Billions of dollars in licensing

revenue hung on the outcome. Doudna chose to focus on the science and the applications,

co-founding Caribou Biosciences in 2011, Intellia Therapeutics in 2014, and later Mammoth

Biosciences and Scribe Therapeutics.

She also helped lead the field through its first ethical reckoning. In January 2015,

eighteen scientists and bioethicists gathered in Napa Valley to discuss the prospect of

editing human germline cells—cells whose changes would pass to future generations. The

group, organized with David Baltimore and others, published “A Prudent Path Forward for

Genomic Engineering and Germline Gene Modification” in

Science

in March 2015: a call for a

moratorium on the clinical use of germline editing and for careful public deliberation.

International summits in Washington followed in 2015 and 2017.

In 2017 she turned to the public directly, publishing

A Crack in Creation

with her colleague

Samuel Sternberg—an account of the discovery addressed to the readers who would inherit

its consequences. The book’s argument was simple: the power to edit life is not inherently

good or bad; it is a tool, and tools ask to be used deliberately.

12 / 24

The Code Breaker Biography by Walter Isaacson — page 13

H A P

V E

Editing the Human Story

2 0 1 6 – 2 0 2 0

he first clinical applications targeted the blood. Sickle cell disease and transfusion-

dependent beta-thalassemia are caused by mutations in a single gene cluster; editing

a patient’s own blood stem cells could, in principle, produce a lifelong cure. By 2018 the first

patients had been enrolled in trials of a treatment called CTX001, which returned edited

stem cells to the body. Early results were startling: patients with beta-thalassemia became

transfusion-independent, and Victoria Gray, the first sickle cell patient treated in the

American trial, was reported free of the painful crises that had punctuated her life.

The same year brought the field its darkest hour. In November 2018, a Chinese

researcher, He Jiankui, announced that twin girls had been born from embryos whose

genomes he had edited—an experiment conducted without clinical justification and, critics

argued, without genuine informed consent. Scientists worldwide condemned the act, and

Doudna was among the first prominent voices to call it a violation of the field’s self-imposed

boundaries. Edits to the germline would be inherited by every future generation, altering

the human gene pool without the consent of those affected. Her distinction was precise:

somatic-cell editing in a sick patient is a therapy; germline editing of an embryo is a social

decision of a different order.

She spent the following years working at the boundary of science and governance—

serving on the international commission on heritable genome editing, testifying about

oversight, funding research on equitable access, and building the Innovative Genomics

Institute into a bridge between the laboratory and the community. The question that

organized her work was deceptively simple: how does a field that moves this fast make sure

that society keeps up?

13 / 24

The Code Breaker Biography by Walter Isaacson — page 14

H A P

I G

H T

The Code Against the Virus

2 0 2 0

n January 2020, as the first cases of a mysterious pneumonia spread beyond Wuhan,

China, Doudna and her colleagues at the Innovative Genomics Institute observed a

strange symmetry. They had spent a decade studying how bacteria defend themselves

against viruses by storing fragments of viral DNA. Now the entire human species faced a

virus, and the same molecular machinery—Cas12, a cousin of Cas9—could be turned into a

detector.

Within weeks, researchers at Mammoth Biosciences and the University of California, San

Francisco had adapted CRISPR-Cas12 into a diagnostic test called DETECTR—DNA

Endonuclease-Targeted CRISPR Trans Reporter. It required no large machines: a nasal

swab, a reaction tube, a strip of paper, and a result in under an hour. The method was

published in

Nature Biotechnology

in the spring of 2020; by summer, the U.S. Food and Drug

Administration had granted emergency-use authorization to two CRISPR-based tests—

Sherlock in May and DETECTR in August.

Around the same time, the Institute launched community testing programs in

underserved neighborhoods of the East Bay, working with local public health departments

to bring free, rapid testing where it was most needed. Doudna would later describe those

months as among the most meaningful of her professional life: the code-breaking machine

she had spent years understanding turned out, in an emergency, to be a code-reading

instrument as well.

14 / 24

The Code Breaker Biography by Walter Isaacson — page 15

H A P

I N

Stockholm in a Sickroom World

2 0 2 0

he call came on the morning of October 7, 2020. Jennifer Doudna and Emmanuelle

Charpentier had been awarded the Nobel Prize in Chemistry for the development of a

method for genome editing—the CRISPR-Cas9 story in its final, official form. It was the first

time a Nobel science prize had been awarded to two women with no male co-laureate, and

the first time the chemistry prize had ever been shared by two women alone.

The pandemic forced a celebration unlike any other in the prize’s history. There was no

crowded banquet in the Stockholm Concert Hall, no sea of tuxedos; laureates delivered their

lectures by video, the young prize-winners’ week was cancelled, and the ceremony unfolded

before empty chairs. The gold medals and diplomas reached the laureates through quiet,

socially distant ceremonies rather than royal pageantry.

In her acceptance remarks, Doudna directed attention away from herself and toward the

larger meaning: the prize honored not a single experiment but a way of doing science—one

in which curiosity-driven work, asking how bacteria remember their enemies, produced

within a decade a tool at the center of medicine. And it honored something rarer: a

collaboration between two scientists in different countries who had chosen to share rather

than to hoard.

15 / 24

The Code Breaker Biography by Walter Isaacson — page 16

H A P

The Open Book

2 0 2 1 – 2 0 2 6

he reality of the tool arrived in the clinic faster than most dared to hope. In November

2023, the United Kingdom’s Medicines and Healthcare products Regulatory Agency

authorized Casgevy, a CRISPR-based treatment for sickle cell disease and transfusion-

dependent beta-thalassemia—the first approved therapy built on gene editing. In December

2023, the U.S. Food and Drug Administration followed, approving Casgevy for sickle cell

disease in patients twelve and older. The treatment edits a patient’s own stem cells to

reactivate fetal hemoglobin, turning a lifetime of crises into, for many, a single corrected

bloodline. Doudna called it the beginning of a new medical era: not a treatment that

manages a genetic disease, but one that corrects it.

Behind the headline lay a decade of groundwork—trials, manufacturing, regulators, and

the immense technical problem of editing cells outside the body and returning them safely.

Beyond the blood, the CRISPR toolbox continued to multiply. Base editing and prime editing

allowed single-letter corrections. New diagnostics promised fast detection of viruses and

cancer mutations. Agricultural programs edited crops for resilience and nutrition, from

disease-resistant wheat to drought-tolerant rice. The fundamental machine she had helped

decipher became the common property of biology itself.

The hardest questions were never technical. Therapies based on CRISPR cost hundreds

of thousands of dollars at launch, raising urgent questions of equity; access to gene-editing

technology is unevenly spread across the world; and the use of editing in embryos remains

barred in most countries and inadvisable in all. Doudna’s institute and the field’s governing

bodies published careful roadmaps for somatic-cell therapy, and the international

commission on which she served concluded that heritable editing must wait until both the

science and the ethics are ready. That consensus—deliberate, public, and hard-won—she

helped build.

What she returns to, in public talks and in the laboratory, is the longer arc. The discovery

began as a puzzle about bacteria and viruses, pursued for no other reason than that it was

beautiful. The lesson she draws is as simple as it is hard to learn: fundamental curiosity

remains the most reliable engine of practical revolution.

16 / 24

The Code Breaker Biography by Walter Isaacson — page 17

I L O

U E

The Responsibility of Knowing

odes are interesting precisely because they can be read. The genetic code—

deciphered letter by letter in the twentieth century and now editable, word by word,

in the twenty-first—is the longest-running code humans have ever encountered: written by

evolution, read by science, and now, for the first time, open to rewriting.

Jennifer Doudna’s life binds those three acts together. She was raised in a place where

nature was unmissable. She was trained to ask what molecules do, not what they are for.

She helped break the code at exactly the moment biology became an information science.

And when the consequences arrived—in clinics, in courtrooms, in the headlines of a global

scandal, in the urgent demands of a pandemic—she chose to step forward rather than back

into the laboratory.

The story of CRISPR is sometimes told as a race: a race for the discovery, a race for the

patent, a race for the prize. But the longer view suggests something else: a slowly built

commons. The knowledge that began in microbial genomes is now shared across the world’s

laboratories, and the newest tools are refined in a thousand places at once. What remains to

be written is the sentence that no laboratory can compose alone—how the human species

will use, govern, and share the power to edit its own code.

On a hillside above the San Francisco Bay, the institute Doudna helped build continues

its work. Somewhere in its corridors, a student is pipetting a reaction that may become

another generation’s revolution. The code is open. What we write with it is no longer a

scientific question—it is a human one.

17 / 24

The Code Breaker Biography by Walter Isaacson — page 18

A P

D I X

Chronology

compressed

chronology

Jennifer

Doudna

’

life

and

the

CRISPR

field

1964

February 19: Jennifer Anne Doudna is born in Washington, D.C.

. 1971

The Doudna family moves to Hilo, Hawaii.

1985

Receives a B.A. in chemistry from Pomona College.

1985–89

Doctoral research with Jack Szostak at Harvard University on catalytic RNA.

1989

Awarded a Ph.D.; begins postdoctoral work with Thomas Cech at the University of

Colorado, Boulder.

1994

Joins the faculty of Yale University.

1996

Publishes the first high-resolution structure of a catalytic RNA, the P4–P6 domain

of the group I intron.

1997

Named an investigator of the Howard Hughes Medical Institute.

2002

Moves to the University of California, Berkeley; her son, Andrew, is born.

2007

Barrangou and colleagues demonstrate that CRISPR-Cas is an adaptive immune

system in bacteria.

2008

Brouns and colleagues show that CRISPR RNAs guide the destruction of invading

DNA.

2011

The Charpentier laboratory, with Jörg Vogel, identifies tracrRNA; Doudna and

Charpentier meet in San Juan, Puerto Rico, and agree to collaborate.

2011

Caribou Biosciences is founded.

2012

June 28: Jinek, Chylinski, Fonfara, Hauer, Doudna, and Charpentier publish the

programmable CRISPR-Cas9 system in

Science

2013

January: Zhang (Broad) and Church (Harvard) laboratories publish CRISPR-Cas9

editing in mammalian cells; the Doudna and Charpentier laboratories publish

human-cell editing in

eLife

2013

CRISPR Therapeutics and Editas Medicine are founded.

2014

Intellia Therapeutics is founded.

18 / 24

The Code Breaker Biography by Walter Isaacson — page 19

2015

January: Napa Valley meeting; “A Prudent Path Forward” is published in

Science

March.

2015

Receives the Breakthrough Prize in Life Sciences and the Gruber Prize in Genetics;

elected to the National Academy of Sciences.

2015

Co-founds the Innovative Genomics Institute at UC Berkeley.

2016

Receives the Tang Prize and the Canada Gairdner International Award; elected a

Foreign Member of the Royal Society.

2017

Receives the Japan Prize with Emmanuelle Charpentier; publishes

A Crack in Creation

with Samuel Sternberg.

2017

February: the U.S. Patent Trial and Appeal Board upholds the Broad Institute’s

eukaryotic-cell patents.

2018

Mammoth Biosciences and Scribe Therapeutics are founded.

2018

November: He Jiankui announces the birth of gene-edited twins; scientists

worldwide condemn the experiment.

2020

January–April: CRISPR-Cas12-based detection of SARS-CoV-2 (DETECTR) is

developed and published.

2020

May and August: the FDA grants emergency-use authorization to the Sherlock and

DETECTR CRISPR tests.

2020

October 7: Doudna and Charpentier are awarded the Nobel Prize in Chemistry.

2021

The International Commission on the Clinical Use of Human Germline Genome

Editing issues its report,

Heritable Human Genome Editing

2023

November 16: the UK MHRA authorizes Casgevy; December 8: the FDA approves

Casgevy for sickle cell disease—the first approved therapies built on CRISPR.

2025

Doudna is awarded the National Medal of Science.

19 / 24

The Code Breaker Biography by Walter Isaacson — page 20

A P

D I X

Principal Achievements

Pioneered the structural biology of RNA.

Solved the first high-resolution structure of

a catalytic RNA and illuminated the architecture of protein-RNA machines such as the

signal recognition particle.

II.

Co-discovered the CRISPR-Cas9 system.

With Emmanuelle Charpentier and

colleagues, demonstrated in 2012 that Cas9 could be programmed with a single guide

RNA to cut any chosen DNA sequence.

III.

Founded the field of CRISPR-based genome editing.

Helped establish that the

bacterial immune system could be repurposed as a universal editing tool in human

and other eukaryotic cells.

IV.

Built the Innovative Genomics Institute.

Co-founded and directed the Berkeley

institute bridging discovery, medicine, agriculture, and community engagement.

Invented CRISPR-based diagnostics.

Co-developed DETECTR, a Cas12-based SARS-

CoV-2 test that received FDA emergency-use authorization in 2020.

VI.

Translated the science into companies.

Co-founded Caribou Biosciences, Intellia

Therapeutics, Mammoth Biosciences, and Scribe Therapeutics.

VII.

Led the ethics of genome editing.

Co-authored “A Prudent Path Forward”; served on

the international commission on heritable human genome editing; advocated for a

moratorium on germline editing.

VIII.

Wrote for the public.

Published

A Crack in Creation

with Samuel Sternberg, one of the

first extended accounts of the discovery and its moral terrain.

IX.

Mentored a generation.

Trained dozens of structural biologists and biochemists who

now hold faculty and industry positions around the world.

20 / 24

The Code Breaker Biography by Walter Isaacson — page 21

A P

D I X

Honors and Awards

E L E C T E D

H O N O R S

I N

C H R O N O L O G I C A L

O R D E R

Y E AR

HO NO R

PRE SE NT E D

B Y

1997

HHMI Investigator

Howard Hughes Medical

Institute

2015

Breakthrough Prize in Life Sciences (with E.

Charpentier)

Breakthrough Foundation

2015

Gruber Prize in Genetics (with E. Charpentier)

Gruber Foundation

2015

100 Most Influential People

Time

magazine

2015

Elected Member

National Academy of Sciences

2016

Tang Prize in Biopharmaceutical Science (with E.

Charpentier)

Tang Prize Foundation

2016

Canada Gairdner International Award (with E.

Charpentier)

Gairdner Foundation

2016

Elected Foreign Member

Royal Society, London

2017

Japan Prize (with E. Charpentier)

Japan Prize Foundation

2017

Albany Medical Center Prize (shared)

Albany Medical Center

2020

Wolf Prize in Medicine (with E. Charpentier)

Wolf Foundation

2020

Nobel Prize in Chemistry (with E. Charpentier)

Royal Swedish Academy of

Sciences

2025

National Medal of Science

President of the United States

21 / 24

The Code Breaker Biography by Walter Isaacson — page 22

A P

D I X

Legacy

The historical significance of Doudna’s work is not that a single enzyme was discovered.

History will remember that a fundamental question—how do bacteria resist viruses?—was

answered so completely that it became technology. CRISPR biology now underpins a global

enterprise: academic laboratories, biotechnology companies, agricultural research, and a

diagnostics industry that proved its worth during a pandemic.

Her example has also reshaped the culture of biology. She modeled open collaboration at a

moment when rivalries were fierce; she built institutes that put basic scientists and

clinicians in the same corridors; and she insisted that the scientists who create powerful

technologies have a duty to help govern them. As one of the most visible women in the

history of biochemistry, she changed the picture of what a field-defining scientist looks like

—a result she has described as mattering to her as much as any structure or prize.

Twenty years from now the textbooks will compress the story into a paragraph: in 2012, a

bacterial immune system became a genome editor; within a decade, the first edited

therapies reached patients; within two, the ethical questions reached every government on

Earth. But the deeper legacy is the demonstration that curiosity-driven science—patient,

open, and unhurried—remains the surest path to the discoveries that change the world.

That lesson, more than any enzyme, is Jennifer Doudna’s bequest.

22 / 24

The Code Breaker Biography by Walter Isaacson — page 23

A P

D I X

A Note on Sources

This biography was prepared as an original work of nonfiction. The factual record was

assembled and cross-checked against primary and institutional sources in the public

domain; the narrative voice, interpretation, and structure are original to this edition. The

following sources were among those consulted for verification.

Source note: where institutional announcements conflicted, the primary record—journal articles,

patent-office decisions, and regulatory authorizations—was given precedence.

1. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012).

A programmable dual-

RNA–guided DNA endonuclease in adaptive bacterial immunity. Science

, 337(6096), 816–821.

2. Deltcheva, E., et al. (2011).

CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.

Nature

, 471, 602–607.

3. Cong, L., et al. (2013).

Multiplex genome engineering using CRISPR/Cas systems. Science

, 339(6121), 819–823; and

Mali, P., et al. (2013).

RNA-guided human genome engineering via Cas9. Science

, 339(6121), 823–826.

4. Broughton, J. P., et al. (2020).

CRISPR–Cas12-based detection of SARS-CoV-2. Nature Biotechnology

, 38, 870–874.

5. Baltimore, D., et al. (2015).

A prudent path forward for genomic engineering and germline gene modification.

Science

, 348(6230), 36–38.

6. International Commission on the Clinical Use of Human Germline Genome Editing (2021).

Heritable Human

Genome Editing.

Washington, D.C.: National Academies Press, with the Royal Society.

7. The Nobel Prize in Chemistry 2020: official announcement, scientific background, and biographical

material. NobelPrize.org, Royal Swedish Academy of Sciences.

8. U.S. Food and Drug Administration (December 8, 2023).

FDA approves first gene editing therapy for sickle cell

disease

(news release, Casgevy).

9. Medicines and Healthcare products Regulatory Agency (November 16, 2023).

MHRA authorizes Casgevy for

sickle cell disease and transfusion-dependent beta-thalassaemia

(news release).

10. Institutional profiles and press materials: Howard Hughes Medical Institute; University of California,

Berkeley; Innovative Genomics Institute; U.S. National Academy of Sciences.

23 / 24

The Code Breaker Biography by Walter Isaacson — page 24

C O L O P

H O N

The text of this edition was set in Source Serif 4, with Playfair Display and

Inter for display, small-caps, and numeric accents. The document was

designed for A4 print production, with page numbers set in the outer margin

footline. First edition, 2026. This volume is an independent biographical

reference edition, prepared without affiliation to, or endorsement by, the

individuals and institutions discussed within it.

◆

24 / 24

The Code Breaker Biography by Walter Isaacson

Prompt to Clone This The Code Breaker Biography by Walter Isaacson

Apply this example's core structure, strategic pacing, and structural hierarchy directly to your own topic.

What are you generating today?